PapersFlow Research Brief
Prostate Cancer Treatment and Research
Research Guide
What is Prostate Cancer Treatment and Research?
Prostate Cancer Treatment and Research encompasses clinical therapies such as chemotherapy, immunotherapy, androgen deprivation, and targeted agents alongside genomic studies to improve outcomes in localized, metastatic, and castration-resistant prostate cancer.
The field includes 119,017 published works on treatments like docetaxel, enzalutamide, abiraterone, and sipuleucel-T, which have demonstrated survival benefits in advanced disease. Tannock et al. (2004) in 'Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer' showed docetaxel every three weeks with prednisone improved survival, pain response, PSA levels, and quality of life over mitoxantrone plus prednisone. D’Amico (1998) in 'Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer' found no significant 5-year PSA outcome differences for low-risk patients across radical prostatectomy, radiation therapy, or implant, but better results with surgery or external beam for intermediate- and high-risk cases.
Research Sub-Topics
Androgen Receptor Signaling in Prostate Cancer
AR signaling drives prostate cancer progression, targeted by enzalutamide and abiraterone. Researchers study resistance mechanisms including AR variants and splice isoforms.
TMPRSS2-ERG Gene Fusion
TMPRSS2-ERG fusion occurs in 50% of prostate cancers via ETS rearrangement. Researchers investigate fusion-driven oncogenesis and diagnostic/prognostic biomarkers.
Prostate Cancer Genomic Profiling
Integrative genomics reveal PTEN loss, SPOP mutations, and ETS fusions across prostate cancer. Researchers correlate genomic subtypes with aggressiveness and therapeutic response.
Prostate Cancer Immunotherapy
Sipuleucel-T vaccine and checkpoint inhibitors target prostate tumor microenvironment. Researchers study PSA-specific T-cells and immunosuppressive myeloid cells.
Prostate Cancer Screening Trials
PSA screening trials (ERSPC, PLCO) balance mortality reduction against overdiagnosis. Researchers develop risk calculators and multiparametric MRI for selective biopsy.
Why It Matters
Prostate cancer treatments have extended survival in metastatic castration-resistant cases, as shown by Scher et al. (2012) where enzalutamide prolonged survival post-chemotherapy in the AFFIRM trial (NCT00974311), with 4508 citations reflecting its clinical adoption. Kantoff et al. (2010) demonstrated sipuleucel-T immunotherapy increased overall survival by months in metastatic castration-resistant prostate cancer without affecting disease progression time, influencing FDA approval and use in over 1000 patients in the trial (NCT00065442). De Bono et al. (2011) reported abiraterone acetate, inhibiting androgen biosynthesis, extended survival in post-chemotherapy patients in the COU-AA-301 trial (NCT00638690), leading to its standard integration with prednisone in advanced disease management across oncology centers.
Reading Guide
Where to Start
'Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer' by Tannock et al. (2004), as it establishes the survival benchmark for chemotherapy in advanced disease with clear comparisons to prior standards.
Key Papers Explained
Tannock et al. (2004) 'Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer' set the chemotherapy standard, which Petrylak et al. (2004) 'Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer' built on by adding estramustine for a nearly two-month median survival gain. Kantoff et al. (2010) 'Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer' introduced immunotherapy survival benefits post-chemotherapy, complemented by Scher et al. (2012) 'Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy' and de Bono et al. (2011) 'Abiraterone and Increased Survival in Metastatic Prostate Cancer' for post-chemo hormonal agents. Tomlins et al. (2005) 'Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer' provides genomic foundations linking to Taylor et al. (2010) 'Integrative Genomic Profiling of Human Prostate Cancer' and Robinson et al. (2015) 'Integrative Clinical Genomics of Advanced Prostate Cancer'.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints highlight personalized intensification of hormone-sensitive prostate cancer treatment beyond ADT alone, efficacy of ADT with ARPIs in metastatic castration-sensitive cases from ARANOTE data, PSMA-based therapy sequencing, and expanded targeted agents beyond ARPI. News covers Case Western Reserve's advanced treatment reducing side effects, NSD2 targeting for drug resistance reversal, and expanded abiraterone access in England.
Papers at a Glance
In the News
Researchers develop treatment for advanced prostate ...
Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving ...
Open RFA/RFPs | Prostate Cancer Foundation
Keep me informed with the latest research news, prostate cancer breakthroughs, patient stories, and ways to get involved.
NSD2 targeting reverses plasticity and drug resistance in prostate cancer
* Published:26 November 2025# NSD2 targeting reverses plasticity and drug resistance in prostate cancer
Personalized intensification of treatment for hormone-sensitive prostate cancer
Historically, systemic therapy for hormone-sensitive prostate cancer (HSPC) was predicated on androgen-deprivation therapy (ADT) alone. However, in the past decade, substantial improvements have be...
Cancer News
* Charity News * For Researchers * For Supporters * Health & Medicine# Thousands more men in England offered abiraterone, one of our prostate cancer treatment breakthroughs
Code & Tools
**PortPy**, short for**P**lanning and**O**ptimization for**R**adiation**T**herapy, is an initiative aimed at creating an open-source Python library...
TensorFlow implementation of our paper: "Automated detection of aggressive and indolent prostate cancer on magnetic resonance imaging [Medical Phys...
healthcare cancer-research cancer-detection prostate-cancer machinelearning-python prostate-cancer-detection prostate-cancer-biopsies Update...
Pull requests Developing the framework to model disease progression in prostate cancer mouse models Updated Jupyt...
Prostata is a natural history model of prostate cancer model which extends the model developed by Ruth Etzioni and colleagues at the Fred\ Hutchins...
Recent Preprints
Personalized intensification of treatment for hormone-sensitive prostate cancer
Historically, systemic therapy for hormone-sensitive prostate cancer (HSPC) was predicated on androgen-deprivation therapy (ADT) alone. However, in the past decade, substantial improvements have be...
Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data
Despite the proven efficacy of androgen deprivation therapy (ADT) combined with androgen receptor pathway inhibitors (ARPIs) in metastatic castration-sensitive prostate cancer (mCSPC), many patient...
Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer
Prostate-specific membrane antigen (PSMA) is upregulated in prostate cancer cells relative to other cells. The increased expression and enzymatic activity of PSMA in high-stage disease confers a se...
New frontiers in prostate cancer treatment from systemic therapy to targeted therapy
Significant advances in prostate cancer (PCa) treatment have occurred through the integration of molecular biomarkers and imaging with targeted therapies. While androgen receptor pathway inhibition...
Latest Developments
Recent developments in prostate cancer treatment and research include the launch of a phase III clinical trial by the Alliance for Clinical Trials in Oncology to optimize radiation timing for advanced prostate cancer (allianceforclinicaltrialsinoncology.org, January 2026), a novel clinical trial at UCLA combining focused radiation with targeted radioactive therapy for recurrent prostate cancer (UCLA Health, January 2026), and the FDA expansion in 2025 for using Pluvicto in earlier treatment lines for PSMA-positive metastatic castration-resistant prostate cancer (Stanford Medicine, August 2025). Additionally, promising research includes the use of engineered immune cells earning an $18 million DOD grant (Virginia Commonwealth University, January 2026), and ongoing phase 3 trials investigating radioligand therapy with [177Lu]Lu-PSMA-617 for taxane-naive metastatic castration-resistant prostate cancer (The Lancet01653-2/abstract), September 2024).
Sources
Frequently Asked Questions
What survival benefits did docetaxel provide over mitoxantrone in advanced prostate cancer?
Tannock et al. (2004) in 'Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer' found docetaxel every three weeks with prednisone led to superior survival and improved pain response, serum PSA levels, and quality of life compared to mitoxantrone plus prednisone. This regimen became a standard for advanced disease based on these outcomes.
How does sipuleucel-T affect outcomes in castration-resistant prostate cancer?
Kantoff et al. (2010) in 'Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer' showed sipuleucel-T prolonged overall survival in men with metastatic castration-resistant prostate cancer. No effect on time to disease progression was observed in the trial (NCT00065442).
What are the PSA outcomes for different treatments in localized prostate cancer?
D’Amico (1998) in 'Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer' reported similar 5-year PSA outcomes for low-risk patients across radical prostatectomy, external beam radiation, or implant with or without neoadjuvant androgen deprivation. Intermediate- and high-risk patients had better outcomes with prostatectomy or external beam than implant.
What genomic alterations are recurrent in prostate cancer?
Tomlins et al. (2005) in 'Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer' identified recurrent TMPRSS2-ERG and TMPRSS2-ETV1 fusions using bioinformatics on outlier gene expression. These chromosomal rearrangements represent oncogenic aberrations in prostate tumors.
How effective is abiraterone in metastatic castration-resistant prostate cancer?
De Bono et al. (2011) in 'Abiraterone and Increased Survival in Metastatic Prostate Cancer' showed abiraterone acetate prolonged overall survival in patients who had received prior chemotherapy. The drug inhibits androgen biosynthesis and was tested in the COU-AA-301 trial (NCT00638690).
What is the impact of PSA screening on prostate cancer mortality?
Schröder et al. (2009) in 'Screening and Prostate-Cancer Mortality in a Randomized European Study' found PSA-based screening reduced prostate cancer death by 20%. It was associated with a high risk of overdiagnosis in the trial (ISRCTN49127736).
Open Research Questions
- ? How can TMPRSS2-ETS fusions identified by Tomlins et al. (2005) be targeted therapeutically in prostate cancer?
- ? What mechanisms underlie treatment resistance in castration-resistant prostate cancer as profiled in integrative genomics studies like Taylor et al. (2010)?
- ? How do sequencing strategies for combining ARPIs, docetaxel, and PSMA therapies optimize outcomes in metastatic castration-sensitive prostate cancer?
- ? What drives plasticity and drug resistance reversible by NSD2 targeting in advanced prostate cancer?
- ? Which biomarkers from integrative clinical genomics like Robinson et al. (2015) predict response to enzalutamide or abiraterone?
Recent Trends
Preprints from late 2025 emphasize intensified ADT combinations with ARPIs for hormone-sensitive and metastatic castration-sensitive prostate cancer, including ARANOTE final data and PSMA therapy sequencing.
News reports NSD2 targeting to reverse plasticity and resistance (November 2025), a Case Western Reserve treatment eliminating debilitating side effects (January 2026), and thousands more men in England receiving abiraterone, one of the breakthroughs.
Research Prostate Cancer Treatment and Research with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Prostate Cancer Treatment and Research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.